Abstract
In spite of almost 60 years of experience with the pharmacological treatment of schizophrenia, there is still a large unmet medical need for better control of especially the negative and cognitive symptoms of schizophrenia. One potential new avenue is the selective blockade of histamine H3 receptors (H3R). Based on a large basis of preclinical data, H3R antagonists or inverse agonists have been suggested to improve cognition in a variety of neurological and psychiatric indications. The aim of the present paper is to review the potential usefulness of H3R antagonists for the treatment of schizophrenia. Although, so far no H3R antagonist has been marketed and many phase II and III studies are still underway, the available data seem to indicate that H3R antagonists may not be primarily effective against the positive symptoms (i.e. the psychotic symptoms such as hallucinations and delusions) but may hold a promise as add-on therapy for selectively improving cognitive and perhaps negative symptoms.
Keywords: Schziphrenia, positive symptoms, cognitive symptoms, animal models, H3 receptors, drug discovery.
Current Pharmaceutical Design
Title:Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?
Volume: 21 Issue: 26
Author(s): Bart A. Ellenbroek and Bibinaz Ghiabi
Affiliation:
Keywords: Schziphrenia, positive symptoms, cognitive symptoms, animal models, H3 receptors, drug discovery.
Abstract: In spite of almost 60 years of experience with the pharmacological treatment of schizophrenia, there is still a large unmet medical need for better control of especially the negative and cognitive symptoms of schizophrenia. One potential new avenue is the selective blockade of histamine H3 receptors (H3R). Based on a large basis of preclinical data, H3R antagonists or inverse agonists have been suggested to improve cognition in a variety of neurological and psychiatric indications. The aim of the present paper is to review the potential usefulness of H3R antagonists for the treatment of schizophrenia. Although, so far no H3R antagonist has been marketed and many phase II and III studies are still underway, the available data seem to indicate that H3R antagonists may not be primarily effective against the positive symptoms (i.e. the psychotic symptoms such as hallucinations and delusions) but may hold a promise as add-on therapy for selectively improving cognitive and perhaps negative symptoms.
Export Options
About this article
Cite this article as:
Ellenbroek A. Bart and Ghiabi Bibinaz, Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?, Current Pharmaceutical Design 2015; 21 (26) . https://dx.doi.org/10.2174/1381612821666150605105325
DOI https://dx.doi.org/10.2174/1381612821666150605105325 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy
Current Clinical Pharmacology Chemistry and Health Effects of Bioactive Compounds in Selected Culinary Aromatic Herbs
Current Nutrition & Food Science Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) The Neuropharmacology of (-)-Stepholidine and its Potential Applications
Current Neuropharmacology Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges
Current Vascular Pharmacology Three-phase Hollow fiber Liquid-phase Micro Extraction for Determination and Analysis of Terazosin in Biological Fluids Via High Performance Liquid Chromatography at Trace Levels
Current Analytical Chemistry Transdermal Delivery of Lercanidipine Hydrochloride: Effect of Chemical Enhancers and Ultrasound
Current Drug Delivery Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
Current Drug Safety Nutrition Status and Weight Management in Chinese Women
Current Women`s Health Reviews Therapeutic Targeting of the Soluble Guanylate Cyclase
Current Medicinal Chemistry Phosphodiesterase 5 Inhibitors - Drug Design and Differentiation Based on Selectivity, Pharmacokinetic and Efficacy Profiles
Current Pharmaceutical Design Vascular Calcifications in Chronic Kidney Disease: Are There New Treatments?
Current Vascular Pharmacology Polypharmacy in Cardiovascular Medicine: Problems and Promises!
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial [Hot Topic: Opportunities and Potential Challenges for the Treatment of Metabolic Syndrome (Guest Editors: Kak-Shan Shia and Yu-Sheng Chao)]
Current Topics in Medicinal Chemistry Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery Supramolecular Chiro-Biomedical Aspect of β-Blockers in Drug Development
Current Drug Targets Targeting Nitrosative Stress for Neurovascular Protection: New Implications in Brain Diseases
Current Drug Targets Analytical Models For Genetics of Human Traits Influenced By Sex
Current Genomics MicroRNAs in Cardiovascular Therapeutics
Current Topics in Medicinal Chemistry